MX387200B - Extracto de streptococcus uberis como agente inmunogénico. - Google Patents

Extracto de streptococcus uberis como agente inmunogénico.

Info

Publication number
MX387200B
MX387200B MX2018009048A MX2018009048A MX387200B MX 387200 B MX387200 B MX 387200B MX 2018009048 A MX2018009048 A MX 2018009048A MX 2018009048 A MX2018009048 A MX 2018009048A MX 387200 B MX387200 B MX 387200B
Authority
MX
Mexico
Prior art keywords
relates
immunogenic agent
biofilm
agent
extract
Prior art date
Application number
MX2018009048A
Other languages
English (en)
Other versions
MX2018009048A (es
Inventor
I Amargós Antoni Prenafeta
Gimbert Rosa Maria Collado
Original Assignee
Hipra Scient S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hipra Scient S L U filed Critical Hipra Scient S L U
Publication of MX2018009048A publication Critical patent/MX2018009048A/es
Publication of MX387200B publication Critical patent/MX387200B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un extracto de Streptococcus uberis como agente inmunogénico. También, se refiere a un procedimiento de obtención de dicho agente que comprende incubar una cepa de S. uberis productora de biofilm para obtener un biofilm y tratar térmicamente el biofilm obtenido. Además, se refiere a una composición farmacéutica que comprende ácidos teicoicos, preferiblemente ácidos lipoteicoicos, para su uso en la prevención y/o el tratamiento de la mastitis y/o de infecciones causadas por Streptococcus sp. o por bacterias productoras de biofilm. La presente invención también se refiere a una vacuna que comprende dicho agente inmunogénico y a dicha vacuna y agente inmunogénico para su uso en la prevención y/o el tratamiento de infecciones causadas por Streptococcus sp., especialmente en la prevención y/o el tratamiento de la mastitis causada por S. uberis. Además se refiere a un kit de vacunación que comprende dicho agente o vacuna.
MX2018009048A 2016-02-15 2017-02-14 Extracto de streptococcus uberis como agente inmunogénico. MX387200B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382060 2016-02-15
PCT/EP2017/053306 WO2017140683A2 (en) 2016-02-15 2017-02-14 Streptococcus uberis extract as an immunogenic agent

Publications (2)

Publication Number Publication Date
MX2018009048A MX2018009048A (es) 2019-03-28
MX387200B true MX387200B (es) 2025-03-18

Family

ID=55646514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009048A MX387200B (es) 2016-02-15 2017-02-14 Extracto de streptococcus uberis como agente inmunogénico.

Country Status (11)

Country Link
US (1) US10946085B2 (es)
EP (1) EP3417049B1 (es)
JP (1) JP6839199B2 (es)
KR (1) KR102824686B1 (es)
AU (1) AU2017220528A1 (es)
CA (1) CA3012419A1 (es)
ES (1) ES2960326T3 (es)
MX (1) MX387200B (es)
PL (1) PL3417049T3 (es)
WO (1) WO2017140683A2 (es)
ZA (1) ZA201805039B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048111A1 (ja) 2021-09-21 2023-03-30 国立研究開発法人 農業・食品産業技術総合研究機構 無莢膜株を抗原として含むワクチン
EP4570265A1 (en) 2023-12-15 2025-06-18 Zaklad Badawczo-Wdrozeniowy Osrodka Salmonella "Immunolab" Sp. z o.o. Vaccine for use in preventing inflammatory conditions in cows

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60243024A (ja) * 1983-12-29 1985-12-03 Kitasato Inst:The ストレプトコツカス・サンギス感染症予防用ワクチン，診断用抗原および抗体
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
DK0832239T3 (da) 1995-06-08 2006-07-31 Univ Saskatchewan CAMP faktor af streptococcus uberis
WO2001096381A2 (en) 2000-06-12 2001-12-20 University Of Saskatchewan IMMUNIZATION OF DAIRY CATTLE WITH GapC PROTEIN AGAINST STREPTOCOCCUS INFECTION
US20070231335A1 (en) * 2005-07-20 2007-10-04 Bruce Beutler Compositions and methods for treating Gram positive bacterial infection in a mammalian subject
PT2484375T (pt) 2006-09-26 2018-07-09 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20110028407A1 (en) * 2007-02-09 2011-02-03 Jutila Mark A Enhancement of innate resistance to infection
GB0818231D0 (en) 2008-10-06 2008-11-12 Univ Nottingham Composition
EP3461496B1 (en) * 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2012116447A1 (en) 2011-03-03 2012-09-07 The Governors Of The University Of Alberta Use of bacterial endotoxins and lipoteichoic acids to improve postpartal health and productivity of dairy cows and their newborns
BR112013028772A2 (pt) * 2011-05-12 2017-01-24 Intervet Int Bv composição veterinária para administração intramamária, e, kit
BR112013032675A2 (pt) * 2011-06-19 2017-08-08 Vaxine Pty Ltd composição adjuvante de vacina compreendendo partículas de inulina
WO2015042369A2 (en) 2013-09-19 2015-03-26 Zoetis Llc Oil-based adjuvants

Also Published As

Publication number Publication date
EP3417049B1 (en) 2023-08-16
JP6839199B2 (ja) 2021-03-03
ZA201805039B (en) 2020-05-27
AU2017220528A1 (en) 2018-08-09
US20190038736A1 (en) 2019-02-07
PL3417049T3 (pl) 2024-02-19
EP3417049A2 (en) 2018-12-26
CA3012419A1 (en) 2017-08-24
JP2019504623A (ja) 2019-02-21
WO2017140683A3 (en) 2017-10-12
KR102824686B1 (ko) 2025-06-25
ES2960326T3 (es) 2024-03-04
US10946085B2 (en) 2021-03-16
BR112018015255A2 (pt) 2018-12-18
WO2017140683A2 (en) 2017-08-24
MX2018009048A (es) 2019-03-28
KR20180108619A (ko) 2018-10-04

Similar Documents

Publication Publication Date Title
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
EP4477662A3 (en) Nucleic acid molecules and uses thereof
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2017015881A (es) Formulaciones para vacunas contra la neoplasia y metodos para preparar las mismas.
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
PH12016501988A1 (en) Antibacterial compounds
MX381211B (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
BR112016023613A2 (pt) novo bacteriófago e composição compreendendo o mesmo
MX378266B (es) Inhibidores de gingipaina de lisina.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
TN2016000435A1 (en) Novel macrocyclic compounds.
MX389771B (es) Compuestos de minociclina para biodefensas.
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
CL2019001649A1 (es) Método para el control de enfermedades bacterianas de plantas utilizando derivados de carboxamida.
MX2022003871A (es) Composiciones inmunogénicas.
MX387200B (es) Extracto de streptococcus uberis como agente inmunogénico.
EP4480541A3 (en) Ketone inhibitors of lysine gingipain
BR112016030728A2 (pt) método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença
BR112016029619A2 (pt) novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas
MX394066B (es) Nuevos compuestos
MX387201B (es) Composiciones para el tratamiento contra infecciones.
BR112018012033A2 (pt) composição imunogênica e método para detectar infecção por h. pylori em um sujeito